 Methamphetamine
"Methamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
| Descriptor ID |
D008694
|
| MeSH Number(s) |
D02.092.471.683.152.619
|
| Concept/Terms |
Methamphetamine- Methamphetamine
- N-Methylamphetamine
- N Methylamphetamine
- Metamfetamine
- Methylamphetamine
- Deoxyephedrine
- Desoxyephedrine
Desoxyn- Desoxyn
- Abbott Brand of Methamphetamine Hydrochloride
Madrine- Madrine
- Langly Brand of Methamphetamine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Methamphetamine".
Below are MeSH descriptors whose meaning is more specific than "Methamphetamine".
This graph shows the total number of publications written about "Methamphetamine" by people in UAMS Profiles by year, and whether "Methamphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 4 | 0 | 4 | | 2022 | 3 | 0 | 3 | | 2021 | 2 | 0 | 2 | | 2020 | 2 | 0 | 2 | | 2019 | 3 | 1 | 4 | | 2018 | 4 | 1 | 5 | | 2017 | 3 | 2 | 5 | | 2016 | 5 | 3 | 8 | | 2015 | 4 | 1 | 5 | | 2014 | 8 | 1 | 9 | | 2013 | 6 | 4 | 10 | | 2012 | 5 | 1 | 6 | | 2011 | 9 | 0 | 9 | | 2010 | 4 | 2 | 6 | | 2009 | 6 | 1 | 7 | | 2008 | 4 | 1 | 5 | | 2007 | 7 | 0 | 7 | | 2006 | 5 | 0 | 5 | | 2005 | 3 | 3 | 6 | | 2004 | 7 | 1 | 8 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 3 | 4 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 2 | 2 | | 1998 | 0 | 2 | 2 | | 1997 | 3 | 1 | 4 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Methamphetamine" by people in Profiles over the past ten years.
-
Pro G, Hayes C, Mancino M. Worsening trends in the frequency of methamphetamine and other stimulant use between treatment admission and discharge. Drug Alcohol Depend. 2024 Sep 01; 262:111403.
-
Pro G, Cantor J, Buttram M, Brown CC, Gu M, Mancino M, Zaller N. Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021. Med Care. 2024 Jul 01; 62(7):464-472.
-
Tackett WR, Yalakala J, Hambuchen MD. Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats. Drug Alcohol Depend. 2024 Jun 01; 259:111301.
-
Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
-
Hiranita T, Ho NP, France CP. Ventilatory Effects of Fentanyl, Heroin, and d-Methamphetamine, Alone and in Mixtures in Male Rats Breathing Normal Air?. J Pharmacol Exp Ther. 2024 01 17; 388(2):244-256.
-
Gorman G, Coward L, Hambuchen MD. Rapid Brain Distribution of Subcutaneously Administered Methamphetamine in Mice. Eur J Drug Metab Pharmacokinet. 2023 01; 48(1):115-118.
-
Rezaeiahari M, Fairman BJ. Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas. Int J Drug Policy. 2022 11; 109:103836.
-
Pro G, Hayes C, Montgomery BEE, Zaller N. Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019. Drug Alcohol Depend. 2022 08 01; 237:109535.
-
McGill MR, Findley DL, Mazur A, Yee EU, Allard FD, Powers A, Coward L, Blough ER, Gorman G, Hambuchen MD. Radiation Effects on Methamphetamine Pharmacokinetics and Pharmacodynamics in Rats. Eur J Drug Metab Pharmacokinet. 2022 May; 47(3):319-330.
-
Thompson RG, Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. J Psychopharmacol. 2021 11; 35(11):1420-1430.
-
Findley DL, Berquist MD, Hambuchen MD. Methamphetamine-Induced Open Field Behavior and LD50 in Periplaneta americana Cockroaches (Blattodea: Blattidae). J Econ Entomol. 2021 02 09; 114(1):476-480.
-
Berquist MD, McGill MR, Mazur A, Findley DL, Gorman G, Jones CB, Hambuchen MD. Effect of bile duct ligation-induced liver dysfunction on methamphetamine pharmacokinetics in male and female rats. Drug Alcohol Depend. 2020 10 01; 215:108190.
-
Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. J Pharmacol Exp Ther. 2020 07; 374(1):16-23.
-
Bullock TA, Berquist MD, Baker LE. Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. Behav Pharmacol. 2019 10; 30(7):566-573.
-
Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol Exp Ther. 2019 11; 371(2):526-543.
-
Cucciare MA, Ounpraseuth ST, Curran GM, Booth BM. Predictors of mental health and substance use disorder treatment use over 3 years among rural adults using stimulants. Subst Abus. 2019; 40(3):363-370.
-
Hambuchen MD, Berquist MD, Simecka CM, McGill MR, Gunnell MG, Hendrickson HP, Owens SM. Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. J Pharm Pharm Sci. 2019; 22(1):301-312.
-
Gannon BM, Mesmin MP, Sulima A, Rice KC, Collins GT. Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats. Psychopharmacology (Berl). 2019 Mar; 236(3):1031-1041.
-
Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance Use by Stimulant Users: Health Outcomes Over Three Years. J Stud Alcohol Drugs. 2018 09; 79(5):799-807.
-
Hay CE, Gonzalez GA, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse. PLoS One. 2018; 13(6):e0200060.
-
Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J. 2018 02 09; 20(2):29.
-
Kangiser MM, Dwoskin LP, Zheng G, Crooks PA, Stairs DJ. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behav Pharmacol. 2018 02; 29(1):87-97.
-
Cheney AM, Newkirk CN, Nekhavhambe VM, Rotondi MB, Hamilton A. Effects of social and spatial contexts on young latinas' methamphetamine use initiation. J Ethn Subst Abuse. 2018 Jan-Mar; 17(1):32-49.
-
Berquist MD, Thompson NA, Baker LE. Evaluation of training dose in male Sprague-Dawley rats trained to discriminate 4-methylmethcathinone. Psychopharmacology (Berl). 2017 Nov; 234(21):3271-3278.
-
Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT. Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats. Neuropharmacology. 2018 05 15; 134(Pt A):28-35.
-
Gannon BM, Galindo KI, Mesmin MP, Rice KC, Collins GT. Reinforcing Effects of Binary Mixtures of Common Bath Salt Constituents: Studies with 3,4-Methylenedioxypyrovalerone (MDPV), 3,4-Methylenedioxymethcathinone (methylone), and Caffeine in Rats. Neuropsychopharmacology. 2018 03; 43(4):761-769.
-
Cucciare MA, Han X, Timko C, Zaller N, Kennedy KM, Booth BM. Correlates of three-year outpatient medical care use among rural stimulant users. J Subst Abuse Treat. 2017 06; 77:6-12.
-
Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15; 795:143-149.
-
House SJ, Coker JL, Stowe ZN. Perinatal Substance Abuse: At the Clinical Crossroads of Policy and Practice. Am J Psychiatry. 2016 11 01; 173(11):1077-1080.
-
Reichard EE, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharm Res. 2016 12; 33(12):2954-2966.
-
Rosas-Hernandez H, Cuevas E, Lantz SM, Rice KC, Gannon BM, Fantegrossi WE, Gonzalez C, Paule MG, Ali SF. Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells. Neurosci Lett. 2016 08 26; 629:125-130.
-
Hambuchen MD, R?edi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. Hum Vaccin Immunother. 2016 09; 12(9):2240-8.
-
Berquist MD, Traxler HK, Mahler AM, Baker LE. Sensitization to the locomotor stimulant effects of "bath salt" constituents, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug Alcohol Depend. 2016 Jul 01; 164:128-134.
-
Cucciare MA, Han X, Curran GM, Booth BM. Associations Between Religiosity, Perceived Social Support, and Stimulant Use in an Untreated Rural Sample in the U.S.A. Subst Use Misuse. 2016 06 06; 51(7):823-34.
-
Freyberg Z, Sonders MS, Aguilar JI, Hiranita T, Karam CS, Flores J, Pizzo AB, Zhang Y, Farino ZJ, Chen A, Martin CA, Kopajtic TA, Fei H, Hu G, Lin YY, Mosharov EV, McCabe BD, Freyberg R, Wimalasena K, Hsin LW, Sames D, Krantz DE, Katz JL, Sulzer D, Javitch JA. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun. 2016 Feb 16; 7:10652.
-
Nanaware-Kharade N, Thakkar S, Gonzalez GA, Peterson EC. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. Sci Rep. 2015 Jul 10; 5:12060.
-
Hambuchen MD, Carroll FI, R?edi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. J Med Chem. 2015 Jun 11; 58(11):4665-77.
-
Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
-
Milesi-Hall? A, Hambuchen MD, McMillan DE, Michael Owens S. The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug Alcohol Depend. 2015 May 01; 150:164-9.
-
Berquist MD, Peet MM, Baker LE. Behavioral sensitization following concurrent exposure to mephedrone and D-amphetamine in female mice. Behav Pharmacol. 2015 Feb; 26(1-2):180-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|